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Dear Editor, 
Thank you for the reviews of the paper "µ-Opioid receptor activation and 
noradrenaline transport inhibition by tapentadol in rat single locus coeruleus 
neurons."   We have revised the manuscript according to the useful comments of 
the reviewers as outlined below.  We hope the paper is now suitable for 
publication. 
Reviewer: 1 
1. No response needed
2. It would be helpful if the description of the method used to construct the
concentration response curves illustrated in Figure 1 were expanded a little. Were 
these done with cumulative applications of agonists or were they done as 
illustrated in parts A&B as a single concentration/slice followed by application of 
naloxone. The single concentration/slice would surely result in more reliable 
measures.  
For met-enkephalin, 2-3 concentrations per slice were applied because we were less 
concerned about the potency and maximal responses in LC which have been 
determined and published many times, ie. it’s a full agonist versus UK14304 with 
potency similar to previous studies. For the direct comparisons of partial agonists 
we considered it very important to not confound maxima or potency of morphine or 
tapentadol by any possibility of desensitization so only applied a single 
concentration per slice. Similarly in the experiment without MOPr or alpha2 
receptors blocked we applied single concentrations.  These are now stated 
explicitly in the relevant parts of the results section (page ). 
3. The only potentially interesting addition would be to examine the inhibition of
reuptake induced by tapentadol on electrically evoked noradrenergic IPSC. This 
experiment might be a more physiological assessment of an otherwise very 
complete pharmacological assay. Although this experiment would be of interest, it 
does not detract from the quality of the work and presentation of the results and 
should not delay the publication of this work.  
This is an interesting question but it turns out that the effects of NET inhibition on 
alpha2 receptor-mediated slow IPSCs in LC are complicated. Originally Surprenant 
and Williams (JPhysiol 382, 87-103,1986) showed with sharp electrodes that NET 
inhibitors including cocaine and desipramine prolong the IPSP in LC slices. We 
have done several experiments with both cocaine and tapentadol and are finding 
much more complex results on the IPSC in whole cell mode. We find in some cells 
and increase in amplitude with little effect on duration and a large effect only on 
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duration in others. In yet other cells, particularly  at high concentrations, the IPSC 
is suppressed. We think the latter occurs because of inhibition of excitability of LC 
neurons in the slice by higher NA tone.  It will take a lot of work, probably 3-4 
months to complete this study. We would much prefer to more fully understand 
these phenomena and publish them separately than to include preliminary data here 
or, alternatively, greatly delay publication of this study. 
Reviewer: 2 
“.... the major issue with the paper in the current form is that insufficient 
justification is provided for using the LC slice model system in view of the fact that 
the analgesic action of tapentadol and the interaction between its two mechanisms 
of action appears to be predominantly mediated at the spinal level – as reviewed by 
the authors..... The findings thus would be appreciated by a broader audience if 
they were put into the context of the LC’s role in the nociceptive system. 
We have emphasized that we have used LC because it is a very good model for 
MOPr, alpha2 receptor and NAT actions but appreciate some comment on the role 
of LC activity in pain. This is not clear in the literature. Electrical stimulation of the 
LC produces antinocicption but opioids microinjected into LC are analgesic. The 
role of the nucleus itself in pain transmission and modulation are therefore complex 
and this could reflect the role of LC in multiple functions with multiple CNS 
targets. We have already discussed the effects in spinal cord in the discussion. We 
have now included a brief paragraph to discuss the role of LC activity in 
nociception and antinociception near the end of the Discussion. 
“... unique receptor profile of the LC ...”. 
We think it wrong of the reviewer to suggest that there is a “unique receptor profile 
of the LC compared with other systems”.  The only other systems studied with 
tapentadol in any pharmacological detail (relative efficacies)  have been 
heterologous expression systems that have very unnatural, excessive levels of 
MOPr expression.  Where natural expression and efficacy has been examined in 
detail in other neurons, particularly in relation to morphine and tolerance, the 
results have been comparable with LC, suggesting that the MOPr tissue efficacy in 
LC is not unique.  We have revised the last sentence at the top of page 15 to 
emphasise this point for readers not familiar with the issue. 
Minor issues: 
1. Typos in second paragraph of Methods/Preparation of brain Slices (p6)
Corrected. 
2. The number of neurons tested for the interaction between MOPr and NAT
mechanism is not provided (p12) 
N = 5 per data point now included on p13. 
3. Typo in last paragraph p15
Corrected. 
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SUMMARY 
Background and purpose. 
Tapentadol is a novel analgesic that combines moderate µ-opioid receptor (MOPr) 
agonism and noradrenaline reuptake inhibition (NRI) in a single molecule. Both 
mechanisms of action are involved in producing analgesia, however the potency and 
efficacy of tapentadol in individual neurons has not been characterized. 
Experimental approach. 
Whole-cell patch clamp recordings of G-protein-coupled inwardly rectifying K 
(GIRK) currents were made from rat locus coeruleus neurons in brain slices to 
investigate the potency and relative efficacy of tapentadol, and compare its intrinsic 
activity with other clinically used opioids. 
Key results. 
Tapentadol showed agonist activity at MOPr and was approximately 6 times less 
potent than morphine with respect to GIRK current modulation. The intrinsic activity 
of tapentadol was lower than met-enkephalin, morphine and oxycodone, but higher 
than buprenorphine and pentazocine. Tapentadol inhibited the noradrenaline 
transporter (NAT) with potency similar to that at the MOPr. The interaction between 
these two mechanisms of action was additive in individual LC neurons. 
Conclusions and Implications. 
Tapentadol displays similar potency for both MOPr and NAT inhibition in 
functioning neurons. The intrinsic activity of tapentadol at the MOPr lies between that 
of buprenorphine and oxycodone, potentially explaining the favourable MOPr-related 
side effect profile. 
Page 5 of 33
British Pharmacological Society
British Journal of Pharmacology
3 
Keywords. 
Tapentadol, Noradrenalin reuptake inhibitor, Opioid receptor agonist, Locus 
coeruleous, GIRK channels 
Abbreviations: 
ACSF, artificial cerebrospinal fluid; GIRK, G-protein-coupled, inwardly rectifying K 
channel; GTPγS, guanosine 5-3-O-(thio)triphosphate; LC, locus coeruleus; ME, 
[Met]5enkephalin; NA, noradrenaline; NAT, noradrenaline reuptake transporter; 
MOPr, µ-opioid receptor. 
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INTRODUCTION 
Opioid analgesics are the mainstay of drug therapy for management of acute and 
chronic severe pain but their utility is limited by on-target side effects, as well as 
development of tolerance and dependence (Christie, 2008; Williams et al., 2013). One 
approach to limit side effects, tolerance and dependence clinically is to combine a 
MOPr agonist and another analgesic drugs with a different mode of action, which can 
enhance overall analgesic actions and produce opioid sparing effects. (Schroder et al., 
2011; Tzschentke et al., 2007) 
Tapentadol is a centrally acting analgesic that combines MOPr agonism with a similar 
potency for noradrenaline transporter (NAT) inhibition in a single molecule 
(Tzschentke et al., 2007).  The rationale behind this particular combination effect is 
based on findings that both opioid and noradrenergic pathways contribute to 
production of analgesia in different ways, and can synergistically interact at spinal 
and supraspinal levels (Fairbanks and Wilcox, 1999; Ossipov et al., 1982). Although 
tapentadol exhibits approximately 50-fold lower binding affinity for MOPr than 
morphine, its analgesic potency is comparable to morphine for acute and chronic pain 
in animal models (Schiene et al., 2011; Tzschentke et al., 2007), and it is well 
documented that tapentadol has a favorable tolerability in humans, particularly with 
respect to gastrointestinal side effects (Afilalo et al., 2010; Hartrick et al., 2009; 
Lange et al., 2010; Pergolizzi et al., 2012; Tzschentke et al., 2009). 
The mechanisms of action of tapentadol have been studied in in vitro models 
(Tzschentke et al., 2007), as well as in vivo neurochemical and behavioral studies in 
animals (Bee et al., 2011; Schiene et al., 2011; Schroder et al., 2011; Schroder et al., 
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2010; Tzschentke et al., 2012) but little is known about the mechanism of action in 
individual neurons. The locus coeruleus (LC) is the major source of noradrenergic 
innervation of the brain and spinal cord (Foote et al., 1983). LC neurons express both 
MOPr and α2-adrenoceptors that converge via G-protein βγ-subunits to activate a 
single population of inwardly rectifying K (GIRK) channels (North and Williams, 
1985). The LC also expresses a high density of NAT (Schroeter et al., 2000). As such, 
the LC is also a useful model to study inhibition of NAT by assaying enhancement of 
actions of α2-adrenoceptors on GIRK channels (Surprenant and Williams, 1987). 
A previous study of electrical activity of LC neurons in vivo (Torres-Sanchez et al., 
2013) reported that systemic administration of tapentadol inhibits spontaneous action 
potential activity. The authors suggested that the actions of tapentadol on these 
neurons is mediated predominantly by activation of α2-adrenoceptors but the direct 
membrane actions and relative potencies for MOPr and NAT could not be determined 
using this experimental approach. The aim of the present study was to investigate the 
relative potency and efficacy of tapentadol in functioning LC neurons using patch 
clamp recording in brain slices. The results establish that tapentadol is an agonist at 
MOPr with lower intrinsic activity than morphine and oxycodone, but greater than 
that of buprenorphine. Tapentadol has similar potency in single LC neurons for MOPr 
and NAT inhibition. At the cellular level, the interaction between these mechanisms 
on activation of GIRK channels is additive. 
METHODS 
Preparation of brain slices 
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Male Sprague–Dawley rats (3 to 5 weeks-old, n = 114) were used in this study. 
Animals were housed in groups of two to four under a 12 h/12h light–dark cycle at 22 
± 2°C with environmental enrichment and free access to food and water. The Animals 
Ethics Committee of the University of Sydney, Sydney, NSW, Australia, which 
complies with the National Health and Medical Research Council ‘Australian code of 
practice for the care and use of animals for scientific purposes’, approved all 
experiments. 
LC slices were prepared as described previously (Dang et al., 2011; Dang et al., 
2012). Briefly, rats were anesthetized with isoflourane (4% in air), decapitated then 
brains were rapidly removed and blocked.  Horizontal brain slices (260-300 µm 
thick) containing LC were obtain from pons on a vibratome (Leica, VT1000) in 
cooled artificial cerebrospinal fluid (ACSF) containing the following (in mM): 126 
NaCl, 2.5 KCl, 2.4 CaCl2, 1.2 MgCl2, 1.2 NaH2PO4, 21.4 NaHCO3, 11.1 glucose, 
95%O2-5%CO2. Slices were incubated in warm (37°C) oxygenated ACSF for at least 
30 min before recording. 
Electrophysiological Recordings 
Whole-cell voltage-clamp recordings of visualized LC neurons (infrared Dopt optics, 
Multiclamp 700B amplifier from Molecular Devices, CA, USA) were acquired at 
holding potential of -60 mV using Axograph X (Axograph Scientific, Australia) as 
previously described (Dang et al., 2012). Data were sampled at 10 kHz and filtered at 
20-50 Hz. Series resistance (≤ 15 ΜΩ) was compensated by 75% and monitored 
throughout experiments. Patch pipettes with  resistance of 2–4 MΩ were filled with a 
solution containing the following (in mM): 115 K MES (2-[morpholino]- ethane-
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sulfonic acid), 20 NaCl, 1.5 MgCl2, 10 BAPTA, 5 HEPES, 4 Mg- ATP and 0.4 Na-
GTP and pH 7.3–7.4 was adjusted using KOH.  All drugs were applied by superfusion 
of the recording chamber (~2 ml/min, 35˚C).  Bestatin (10 µM) and thiorphan (1 µM) 
were included in all experiments using met-enkephalin to limit degradation of the 
peptide. In all experiments involving application of NA, prazosin (1µM) was included 
for at least 5 min before superfusing NA to prevent potential effects of α1-
adrenoceptor activation on GIRK channels in these neurons (Osborne et al., 2002) 
Solutions of NA were freshly prepared when reapplication time exceeded 5 min to 
avoid oxidative decomposition. A single concentration of tapentadol was applied per 
slice. 
Data analyses 
Data were analyzed using Graph-Pad Prism (Graph-Pad V5), except for 
isobolographic analysis. All data are presented as mean ± SEM. Significant 
differences were analyzed by Student’s t-test (paired or unpaired two-tailed Student’s 
t tests) or, where appropriate, one way ANOVA followed by Dunnett’s test, or two 
way ANOVA followed by Bonferroni post-test. Concentration-response curves were 
calculated for each group and fitted to a logistic equation using Graph-Pad Prism, 
with minima constrained to zero. Isobolographic analysis was performed using a 
modification of the method of (Tallarida, 2007). By this method, additivity is based 
on the concept of concentration equivalence for drug A and B (or dual mechanisms) 
follows from individual concentration-effect curves (Grabovsky and Tallarida, 2004), 
i.e a concentration α of drug A is equal to a concentration of drug B denoted beq (α).
So combinations of these two concentrations (a,b) would be  beq (α) + b. The 
theoretical additive EC50 value was compared with the observed EC50 for the 
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combination by t-test using FlashCalc 4.5.3 (Dr Michael Ossipov, University of 
Arizona, Tucson AZ). 
Drugs: 
Stock solutions of tapentadol HCl supplied by Grünenthal GmbH (Germany), [Met
5
]-
enkephalin (Sigma-Aldrich, Australia), bestatin (Sigma), morphine HCl (GSK 
Australia), idazoxan HCl (Tocris, UK), naloxone HCl (Sigma-Aldrich, Australia), 
noradrenaline (NA; Sigma-Aldrich, Australia), cocaine (GlaxoSmithKline, Australia) 
and oxycodone HCl (National Institute on Drug Abuse Drug Supply Program, 
USA),were dissolved in distilled water. Other drugs included UK 14,304 (Tocris, UK), 
prazosin HCl (Sigma-Aldrich, Australia), dissolved in 20% and 10% dimethyl 
sulfoxide (DMSO) respectively. Thiorphan (Sigma) was dissolved in 50% ethanol. 
(+)-Pentazocine from Research Biochemical (Natick, MA, USA) was dissolved in 
distilled water with 1-2 drops (almost 50 µL) of glacial acetic acid. Buprenorphine 
(National Institute on Drug Abuse Drug Supply Program, USA) was dissolved in 
distilled water using HCI (1M, 1-2 drops). The maximum concentration of DMSO 
used in the superfusion solution was < 0.01% and for ethanol was < 0.0001%. 
RESULTS 
Relative potency and efficacy of tapentadol at µ-opioid receptors. 
To determine the relative potencies and efficacies of tapentadol and several other 
opioids at MOPr, whole-cell patch-clamp of GIRK currents were recorded at a VH of -
60 mV in the presence of idazoxan (1 µM) and prazosin (300 nM) to block any action 
of increased noradrenergic tone that might be caused by tapentadol’s NAT inhibition. 
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Concentration-response curves for met-enkephalin were constructed using 2-3 
concentrations per cell. For morphine and tapentadol concentration-response curves, a 
single concentration of tapentadol or morphine was applied per slice to minimise any 
possibility that desensitization would confound potency or maximal responses. As 
shown in Figure 1A, a supramaximal concentration of tapentadol (30 µM) produced 
an outward current that was consistently smaller than the current produced by a 
supramaximal concentration of the full α2-adrenoceptor agonist UK14304 (3 µM)), in 
the same cells (Table 1). Naloxone (1 µM) fully reversed the effects of tapentadol (n 
= 12). 
As expected from previous studies (Bailey et al., 2009; Dang and Williams, 2005; 
Osborne et al., 2000; Virk and Williams, 2008), the effect of morphine was lower 
than the maximal response produced by met-enkephalin in LC neurons (Figure 1B, 
Table 1), ie. morphine acted as a partial agonist for activation of GIRK in rat LC 
neurons using whole-cell recording in brain slices. The maximum response to 
tapentadol was smaller than that produced by morphine (Table 1) suggesting that 
tapentadol has lower intrinsic efficacy than morphine at the MOPr. 
Met-enkephalin was a potent and efficacious agonist in LC (Figure 1D, Table 1), with 
a response amplitude similar to that produced by UK14304 (3 µM). The maximum 
responses relative to UK14304 (3 µM) for both morphine (30 µM) and tapentadol (30 
µM) were considerably smaller than that produced by met-enkephalin (Table 1). As 
summarized in Table 1, tapentadol is approximately 6-fold less potent than morphine. 
The EC50 for morphine was similar to that previously reported in LC neurons using 
patch-clamp recordings (Osborne et al., 2000). 
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Intrinsic activity of tapentadol relative to other MOPr agonists using partial 
antagonism 
If tapentadol does indeed have lower intrinsic agonist activity than met-enkephalin 
and morphine, it should partially antagonise both agonists. As shown in Figure 2, both 
morphine (Figure 2A) and tapentadol (Figure 2B) partially reduced the actions of a 
supramaximal concentration of met-enkephalin. Moreover, tapentadol partially 
reduced the effect of a supramaximal concentration of morphine (Figure 2C). 
 The relative intrinsic activity of tapentadol was further compared with several other 
clinically used MOPr-agonists including oxycodone, buprenorphine and pentazocine. 
Tapentadol partially reduced the effect of a supramaximal concentration of 
oxycodone (Figure 2D). Because buprenorphine and pentazocine are weak partial 
agonists at MOPr in LC neurons (Virk et al., 2009), producing very small outward 
currents, they were both tested as partial antagonists, with tapentadol applied first. 
Buprenorphine (Figure 2E) and pentazocine (Figure 2F) both antagonised the actions 
of a supramaximal concentration of tapentadol, suggesting that tapentadol has greater 
intrinsic activity than these two partial agonists. 
To test the possibility that tapentadol might inhibit GIRK in LC neurons 
independently of its action on MOPr (as does methadone; (Rodriguez-Martin et al., 
2008)), slices were superfused with naloxone (1 µM), prior to and during application 
of tapentadol in the presence of a supramaximal concentration of UK14304 (Figure 
2G) to fully activate GIRK currents via α2-adrenoceptors.  Prazosin (300 nM) was 
included to avoid potential confounds from activation of α1-adrenoceptors (Osborne et
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al., 2002). Application of a saturating concentration of UK14304 (3µM) induced a 
slowly desensitizing outward current, as previously reported (Dang et al., 2012) but 
tapentadol had no apparent effect on the current (Figure 2G).  To account for the 
decline in the UK14304-induced current due to desensitisation, the slope of the 
declining current was fitted with a linear function prior to application of tapentadol 
and the increased slope produced by tapentadol was calculated. Superfusion of 
tapentadol in the presence of UK14304 did not have any effect on the steady decay of 
the outward current (t = 0.054, P > 0.96 paired t-test, df = 6). These results establish 
that partial antagonism of met-enkephalin, morphine and oxycodone by tapentadol is 
due to its lower intrinsic activity rather than direct block of GIRK channels. 
The actions of tapentadol at the MOPr are summarised in Table 2. The results suggest 
a relative order of intrinsic activity of Met-enkephalin > morphine ≈ oxycodone > 
tapentadol > buprenorphine ≈ pentazocine. 
Tapentadol enhances the action of exogenously applied noradrenaline in LC 
neurons. 
The potency of tapentadol to inhibit NAT and thereby potentiate the actions of NA on 
LC neurons was studied by blocking MOPr, then superfusing a low concentration of 
NA with tapentadol as previously established for the actions of cocaine in LC neurons 
(Surprenant and Williams, 1987). In the presence of naloxone (1 µM) and prazosin 
(300 nM), without addition of NA, tapentadol (100 µM) produced little or no outward 
current (< 5 pA, n = 3, data not shown), suggesting little basal noradrenergic tone in 
slices under the present recording conditions. However, as shown in Figure 3, 
tapentadol potentiated α2-adrenoceptor responses when NA was exogenously applied. 
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Responses to NA (3 or 10 µM) were variable from cell to cell and slice to slice, 
presumably due to variation in the diffusion path through slices to relevant α2-
adrenoceptors, which produced a large variation in subsequent NAT inhibition. 
Indeed, there appeared to be an inverse correlation between the amplitude of response 
to NA and extent of potentiation produced by tapentadol (not shown). To control for 
these differences, the extent of potentiation produced by different concentrations of 
tapentadol was determined only if the initial response to 3 or 10 µM NA was between 
5% (less than 5% was considered too small to calculate a reliable percentage of 
enhancement) and 20% of the maximum response produced by met-enkephalin. 
Tapentadol produced a concentration-dependent enhancement of NA-induced GIRK 
currents in the concentration range of 0.1-30 µM. In the presence of high 
concentrations of tapentadol (30 - 100 µM), no further potentiation of the response to 
NA could be achieved by further addition of a supramaximal concentration of cocaine 
(10 µM; (Surprenant and Williams, 1987) (101 ± 1% of tapentadol response, n = 3)), 
indicating that NAT inhibition was maximal at these concentrations. All subsequent 
data were normalized to the enhancement of outward current produced by a 
supramaximal concentration of cocaine (10 µM). The concentration-response curve 
for tapentadol is presented in Figure 4.  The IC50 for tapentadol at NAT in LC slices 
was 2.3 µM (pIC50 = 5.6 ± 0.1). 
Interaction between the two mechanisms of action of tapentadol in single LC 
neurons 
To test how the combined actions of tapentadol on MOPr and α2-adrenoceptors, via 
NAT inhibition, interact with respect to GIRK currents, tapentadol was applied to LC 
neurons in the presence of a low concentration of NA (3 µM) without addition of 
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antagonists of either receptor. To construct the concentration-response curve, a single 
concentration of tapentadol was applied per slice.  Figure 4A shows the enhancement 
of the effect of NA (3 µM) under these conditions. Data were normalized to the 
maximum GIRK current induced by saturation concentration of UK 14303 (3 µM) 
after subtraction of the small current induced by NA (3 µM). As shown in Figure 4B, 
the potency of tapentadol acting on both MOPr and NAT (EC50 = 2.6 µM , pEC50 = 
5.6 ± 0.1, n = 5 for each concentration of tapentadol) is not significantly different 
from the potency of tapentadol as a NAT inhibitor (EC50 = 2.3 µM, P> 0.05, two-way 
ANOVA, Bonferroni post-test). As confirmed by isobolographic analysis (Grabovsky 
and Tallarida, 2004; Tallarida, 2006), the interaction between these two mechanisms 
of action on a single neuron level was additive (P> 0.15), since the theoretical 
additive EC50 for independent actions on MOPr and NET (3.8 ± 1.2 µM) was not 
significantly different from EC50 for tapentadol with its combined mechanism (2.53 ± 
1.4 µM). 
DISCUSSION 
The present study demonstrates that tapentadol is a MOPr agonist and NAT inhibitor 
in single LC neurons in brain slices.  Tapentadol exhibited 6-fold lower potency than 
morphine for activation of GIRK currents in LC neurons. A previous study 
(Tzschentke et al., 2007), reported that the binding affinity of tapentadol for rat MOPr 
was more than 40-fold lower than that of morphine (Ki = 96 nM for tapentadol versus 
Ki = 2.2 nM for morphine). Similarly, in a human recombinant MOPr  [
35
S]GTPγS
assay tapentadol (EC50 =  670 nM) exhibited approximately 30-fold lower potency 
than morphine (EC50 = 22 nM;  (Tzschentke et al., 2007)).  From this, tapentadol 
would have been expected to exhibit substantially lower potency than morphine in LC 
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neurons. A likely explanation for the smaller differences between the agonist 
potencies of tapentadol and morphine observed here compared with the previous 
study is that MOP receptor reserve is substantially lower in LC neurons than the 
heterologous expression system used previously (Tzschentke et al., 2007). This 
interpretation is consistent with the overall potency difference for morphine (14-fold) 
between the two assay systems. The differences in relative intrinsic activities are also 
consistent with a large difference in receptor reserve. The maximal effect of 
tapentadol was 88% of that of morphine in the previous study (Tzschentke et al., 
2007) but less than 50% in the LC. Agonists with relatively high intrinsic efficacy 
(morphine) are predicted to exhibit greater reduction in EC50 than lower intrinsic 
efficacy agonists when receptor reserve increases (Strange, 2008). It is therefore 
likely that the relative potency and intrinsic activity differences between morphine 
and tapentadol reported here more closely reflect differences in MOPr interaction in 
brain neurons than in previous studies in heterologous expression systems, as 
discussed elsewhere (Law et al., 2000; Morgan and Christie, 2011). 
Tapentadol exhibited a relative intrinsic activity at MOPr with respect to activation of 
GIRK currents that was less than met-enkephalin, morphine and oxycodone but 
greater than the weak partial agonists buprenorphine and pentazocine. This was 
confirmed, where possible, both by examining the relative maximal response to each 
agonist and partial antagonism. Furthermore, the present study confirmed that 
measurement of relative intrinsic activity of tapentadol was not confounded by direct 
block of GIRK channels, as was observed for other opioids such as methadone 
(Rodriguez-Martin et al., 2008). 
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Many studies have sought to separate the analgesic effect of MOPr activation from 
their side effects. It is well established that the MOPr mediates both analgesic activity 
and adverse effects of MOPr agonists (Matthes et al., 1996). Agonists with a 
relatively low intrinsic activity at MOPr could overcome some of the limitations of 
very high intrinsic efficacy MOPr agonists in terms of therapeutic window and side 
effects. Indeed buprenorphine is a very low intrinsic efficacy MOPr agonist, but 
produces strong analgesia, and shows an improved tolerability profile compared with 
morphine (Cowan et al., 1977; Jasinski et al., 1978).  In opioid tolerant individuals, 
buprenorphine also shows a greatly reduced overdose liability (Fatseas and 
Auriacombe, 2007). It is tempting to speculate that favorable tolerability of tapentadol 
in humans, particularly with respect to gastrointestinal side effects (Afilalo et al., 
2010; Hartrick et al., 2009; Lange et al., 2010; Pergolizzi et al., 2012; Tzschentke et
al., 2009), could in part be due to its relative intrinsic activity at MOPr which is 
intermediate between morphine and buprenorphine. 
The present study has also established that tapentadol enhances the outward current 
induced by application of NA in LC neurons by effectively increasing the 
concentration of NA reaching postsynaptic α2-adrenoceptors, as do other NAT 
inhibitors (Surprenant and Williams, 1987). Tapentadol exhibited potency for NAT 
inhibition similar to that for activation of the MOPr. 
The finding that the interaction between the two mechanisms of action of tapentadol 
is additive with respect to activation of GIRK currents in LC neurons is not surprising 
because both mechanisms are known to converge via a common transduction system 
through G-protein βγ-subunits to activate a single population of GIRK channels 
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(North and Williams, 1985; Stone and Wilcox, 2004). However, previous studies have 
demonstrated the interaction between the two mechanism of action of tapentadol in
vivo, which is predominantly mediated at the spinal level, is synergistic rather than 
additive (Schroder et al., 2011).  Possible explanations for the synergistic interaction 
of tapentadol acting on both MOPr and NAT in vivo could be due to receptor 
activation at multiple sites along the physiological pain-modulatory pathways rather 
than being mediated at the single cell level (Stone and Wilcox, 2004). The synergistic 
interaction observed in vivo could include a network effect activation of the 
descending inhibitory pathways at supraspinal level via MOPr activation together 
with potentiation of this effect via NAT inhibition at the spinal level, as well as 
inhibition of nociceptive transmission between primary afferent and spinal second 
order neurons via pre- and postsynaptic MOPr- and α2-adrenoceptors. 
Although the LC is useful to study action of MOPr pharmacology and NAT inhibition 
in neurons, the influence of neuronal activity in the nucleus in pain modulation is not 
fully understood. Electrical or chemical stimulation of LC produces analgesia in acute 
and inflammatory pain states (Jones, 1991; Jones and Gebhart, 1986; West et al., 
1993) as would be expected from enhancement of spinal NA release. However, direct 
inhibition of LC activity by microinjection of MOPr agonists in vivo is also 
antinociceptive (Jongeling et al., 2009). The predicted overall effect of suppression 
of LC neuronal activity by tapentadol on pain modulation in vivo is therefore 
uncertain. 
In conclusion, the present study has established that tapentadol has almost the same 
potency for NAT inhibition and MOPr activation in single functioning neurons. Its 
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reduced intrinsic activity at MOPr compared with morphine, together with its 
inhibition of NET may both contribute to improved tolerability profile. 
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Table 1. Membrane actions, MOPr agonism and potency of tapentadol and other 
opioids in LC neurons 
Imax (pA) Imax/IUK14304 % pEC50  (-log[µM])
a
 EC50 (µM)
tapentadol 91 ± 15 
(n = 12) 
29 ± 4 
*†
5.8 ± 0.2 1.8 
morphine 151 ± 25 
(n = 8) 
59 ± 4
*
6.5 ± 0.3 0.3 
met-enkephalin 222 ± 13 
(n = 5) 
126 ± 7 6.9 ± 0.1 0.13 
Data are expressed as mean mean ± s.e.m. 
a – s.e.m. of  fitted curve 
* - significantly different from met-enkephalin (unpaired t-tests, all P < 0.001)
† - significantly different from morphine (unpaired t-test, all P < 0.001) 
- Data are expressed as mean mean ± s.e.m, and the number of experiments is shown 
in parentheses. 
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Table 2. Relative intrinsic activity of tapentadol and other opioids in LC neurons 
Opioid (n) Iopioid (pA)  Iopioid+tapent (pA) Itapent/opioid  (%) 
met-enkephalin (4) 177 ± 6 26 ± 9 14 ± 5 
Morphine (4) 153 ± 18 73 ± 9
*
48 ± 3 
Oxycodone (7) 209 ± 37 93 ± 27
*
41 ± 5 
Buprenorphine (5) 69 ± 6
a
3.4 ± 1.7
*
n.d. 
Pentazocine (4) 117 ± 17
a
1.3 ± 2.0
*
n.d. 
Data are expressed as mean mean ± s.e.m. 
a –  Itapentadol applied first then combined with listed opioid 
* - significantly different from met-enkephalin (unpaired t-tests, all P < 0.01)
n.d. – not determined 
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Figure1 
GIRK current induced by activation of MOPr in LC neurons. Superfusion (shown by 
bars) of tapentadol (A), morphine (B) and met-enkephalin (ME, C) activate GIRK 
currents at holding potential (-60 mV) in the presence of the α2-adrenoptor antagonist, 
idazoxan. All actions are reversed by the MOPr antagonist, naloxone. D. 
Concentration-response curves for met-enkephalin (black), morphine (red) and 
tapentadol (green). The amplitude of the hyperpolarization plotted as a percentage of 
the amplitude of a supramaximal concentration of UK14304. 
Figure 2 
Intrinsic activity of tapentadol at MOPr (adrenergic receptors were blocked from A-F 
with idazoxan, 1 µM and prazosin 300 nM). A. Morphine (30 µM) reversibly 
antagonized the current induced by a supramaximal (and desensitized) concentration 
of met-enkephalin confirming the lower intrinsic activity of morphine than met-
enkephalin. B. Tapentadol had lower intrinsic activity than met-enkephalin and 
reversibly antagonized the current induced by a supramaximal (desensitized) 
concentration of met-enkephalin. C. Tapentadol partially and reversibly reduced the 
current induced by a supramaximal concentration of morphine. D. Tapentadol 
partially reduced the current induced by a supramaximal concentration of oxycodone. 
E. Buprenorphine and F. Pentazocine almost completely antagonized currents 
induced by a supramaximal concentration of tapentadol. G. Tapentadol did not inhibit 
the current induced by supramaximal concentration of UK14304 in the presence of 
naloxone. 
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Figure 3 
Tapentadol potentiates responses of LC neurons to NA A.   Example showing that 
tapentadol in the continuous presence of NA enhances the outward current induced by 
NA via inhibiting NA reuptake transporter (MOPr blocked by naloxone 1 µM) B. 
Concentration-response curve for potentiation of exogenous NA by tapentadol (IC50 = 
2.3 µM). 
Figure 4 
A. Tapentadol with combined mode of action enhanced the NA effect in single LC 
neurons. All data were normalized by the maximum effect induced by UK 14,304 (3 
µM). B. Comparison between the concentration response- curve of tapentadol as a 
MOPr agonist alone (with adrenergic receptors blocked; blue from Figure 1), 
tapentadol as a NAT inhibitor alone (with MOPr blocked; orange from Figure 3) and 
tapentadol acting on both mechanisms in the absence both MOPr and α2- 
adrenoceptor antagonists (solid curve in green). 
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GIRK current induced by activation of MOPr in LC neurons. Superfusion (shown by bars) of tapentadol  (A), 
morphine (B) and met-enkephalin (ME, C) activate GIRK currents at holding potential (-60 mV) in the 
presence of the α2-adrenoptor antagonist, idazoxan. All actions are reversed by the MOPr antagonist, 
naloxone. D. Concentration-response curves for met-enkephalin (black), morphine (red) and tapentadol 
(green). The amplitude of the hyperpolarization plotted as a percentage of the amplitude of a supramaximal 
concentration of UK14304.  
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Intrinsic activity of tapentadol at MOPr (adrenergic receptors were blocked from A-F with idazoxan, 1 µM 
and prazosin 300 nM). A. Morphine (30 µM) reversibly antagonized the current induced by a supramaximal 
(and desensitized) concentration of met-enkephalin confirming the lower intrinsic activity of morphine than 
met-enkephalin. B. Tapentadol had lower intrinsic activity than met-enkephalin and reversibly antagonized 
the current induced by a supramaximal (desensitized) concentration of met-enkephalin . C. 
Tapentadol  partially and reversibly reduced the current induced by a supramaximal concentration of 
morphine). D. Tapentadol partially reduced the current induced by a supramaximal concentration of 
oxycodone . E. Buprenorphine and F. Pentazocine   almost completely antagonized currents induced by a 
supramaximal concentration of tapentadol . G. Tapentadol did not inhibit the current induced by 
supramaximal concentration of UK14304 in the presence of naloxone.  
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Tapentadol potentiates responses of LC neurons to NA A.   Example showing that tapentadol in the 
continuous presence of NA enhances the outward current induced by NA via inhibiting NA reuptake 
transporter (MOPr blocked by naloxone 1 µM) B. Concentration-response curve for potentiation of 
exogenous NA by tapentadol (IC50 = 2.3 µM).  
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A. Tapentadol with combined mode of action enhanced the NA effect in single LC neurons. All data were 
normalized by the maximum effect induced by UK 14,304 (3 µM). B. Comparison between the concentration 
response- curve of tapentadol as a MOPr agonist alone (with adrenergic receptors blocked; blue from Figure 
1), tapentadol as a NAT inhibitor alone (with MOPr blocked; orange from Figure 3) and tapentadol acting on 
both mechanisms in the absence both MOPr and α2- adrenoceptor antagonists (solid curve in green). 
172x250mm (300 x 300 DPI) 
Page 33 of 33
British Pharmacological Society
British Journal of Pharmacology
